TDRD12: A Potential Drug Target and Biomarker for the Treatment of Human Inherited Disorders

Target Name: TDRD12

NCBI ID: G91646

TDRD12: A Potential Drug Target and Biomarker for the Treatment of Human Inherited Disorders

Introduction

Tetraspan protein is a protein with a wide range of functions within cells, and its family includes TDRD12. TDRD12 is an RNA-binding protein expressed in multiple cell types. TDRD12 is involved in various biological processes in cells, such as cell proliferation, differentiation and tumorigenesis. In recent years, studies have found that TDRD12 is closely related to a variety of genetic diseases and tumorigenesis. TDRD12 has become a molecule that has attracted much attention and has the potential to become a new drug target or biomarker.

Structure and function of TDRD12

TDRD12 is a polypeptide with a length of 294 amino acids and belongs to the Tetraspan family. It consists of two domains: N-terminal 伪-helix and C-terminal 尾-coil. The N-terminal 伪-helix of TDRD12 is composed of 10 伪-helical units, forming 4 尾-伪-helical units. The C-terminal 尾-coil of TDRD12 is composed of 15 尾-helical units, including 2 antiparallel 尾-helical units.

The function of TDRD12 is mainly reflected in its ability as an RNA-binding protein. TDRD12 can bind to a variety of RNA molecules, including mRNA, rRNA, and microRNA (miRNA). By binding to RNA, TDRD12 is involved in regulating biological processes such as gene expression, DNA replication, and cell cycle. In addition, TDRD12 can also bind to some proteins, such as histones, H1 and K1, etc., thereby participating in chromatin structure and function.

The relationship between TDRD12 and various genetic diseases and tumors

TDRD12 is closely related to a variety of genetic diseases and tumorigenesis. Studies have found that TDRD12 is closely related to many genetic diseases, such as neural tube malformations, hemophilia, and congenital anorectal stenosis. The expression level of TDRD12 is positively correlated with the severity and incidence of these diseases. In addition, TDRD12 is also related to the occurrence of various tumors, such as breast cancer, lung cancer, and ovarian cancer. The expression level of TDRD12 is positively correlated with tumor aggressiveness and treatment response.

Pharmacological properties of TDRD12

TDRD12 has a variety of pharmacological properties and is expected to become a new drug target. First, TDRD12 can selectively bind to miRNA, thereby inhibiting the degradation of miRNA. This provides a basis for using TDRD12 as a miRNA target. Secondly, TDRD12 can inhibit DNA replication, thereby inhibiting the growth of tumor cells. In addition, TDRD12 can also induce apoptosis, thereby having a cytotoxic effect on tumor cells.

Biological activity of TDRD12

TDRD12 has multiple biological activities in cells. TDRD12 can bind to a variety of RNA molecules and thus participate in biological processes such as gene expression and cell cycle. TDRD12 can also bind to proteins, such as histones, H1, and K1, thereby participating in chromatin structure and function. In addition, TDRD12 can also participate in biological processes such as cell proliferation, differentiation, and tumorigenesis.

Clinical application prospects of TDRD12

TDRD12 is a molecule with a wide range of biological activities and has great clinical application prospects. First, TDRD12 can be used as a miRNA target to treat miRNA-related genetic diseases, such as neural tube malformations, hemophilia, and congenital anorectal stenosis. Secondly, TDRD12 can be used as an inducer of tumor cell apoptosis to treat a variety of tumors, such as breast cancer, lung cancer, and ovarian cancer. In addition, TDRD12 can also be used as a target for drug research to treat a variety of genetic diseases and tumors.

Conclusion

TDRD12 is a molecule with a wide range of biological activities and is closely related to a variety of genetic diseases and tumorigenesis. TDRD12 has

Protein Name: Tudor Domain Containing 12

Functions: Probable ATP-binding RNA helicase required during spermatogenesis to repress transposable elements and preventing their mobilization, which is essential for the germline integrity. Acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and governs the methylation and subsequent repression of transposons. Involved in the secondary piRNAs metabolic process. Acts via the PET complex, a multiprotein complex required during the secondary piRNAs metabolic process for the PIWIL2 slicing-triggered loading of PIWIL4 piRNAs

More Common Targets